With the confirmed in vitro anti-AML activity in AML cell lines with either FLT3-ITD mutation, or high CSF1R expression, or high CDK6 expression, we decided to test the anti-AML activity of narazaciclib in vivo. Here, FLT3 is linked to acute myeloid leukemia.